ND-646

Research use only, not for human use.

ND-646 is an orally bioavailable and allosteric inhibitor of the ACC enzymes ACC1 and ACC2(IC50s of 3.5 nM and 4.1 nM for recombinant hACC1 and hACC2, respectively)ND-646-an allosteric inhibitor of the ACC enzymes. ACC1 and ACC2 that prevents ACC subunit dimerization-to suppress fatty acid synthesis in vitro and in vivo.

ND-646 is an orally bioavailable and allosteric inhibitor of the ACC enzymes ACC1 and ACC2(IC50s of 3.5 nM and 4.1 nM for recombinant hACC1 and hACC2, respectively)ND-646-an allosteric inhibitor of the ACC enzymes ACC1 and ACC2 that prevents ACC subunit dimerization-to suppress fatty acid synthesis in vitro and in vivo. Chronic ND-646 treatment of xenograft and genetically engineered mouse models of NSCLC inhibited tumor growth. When administered as a single agent or in combination with the standard-of-care drug carboplatin, ND-646 markedly suppressed lung tumor growth in the Kras;Trp53-/- (also known as KRAS p53) and Kras;Stk11-/- (also known as KRAS Lkb1) mouse models of NSCLC.

——

——

——

Others

Other Targets

ACC

——

——

1434639-57-2

568.64

C28H32N4O7S

>98% (HPLC)

DMSO:95 mg/mL (167.06 mM)

COc1ccccc1[C@H](Cn1c2sc(-c3ncco3)c(C)c2c(=O)n(c1=O)C(C)(C)C(N)=O)OC1CCOCC1

——

(-20℃)

With Ice Pack

≥ 2 years